Supplementary Material Table - Real-World Clinical Outcomes of Patients With Myelofibrosis Treated With Ruxolitinib: a Medical Record Review
datasetposted on 2022-04-14, 10:44 authored by Francesco Passamonti, Florian H. Heidel, Rohan C. Parikh, Mayank Ajmera, Derek Tang, Jose Alberto Nadal, Keith L. Davis, Pranav Abraham
Supplemental Table 1. Physician characteristics.
Supplemental Table 2. Symptom characteristics and distribution at ruxolitinib initiation.
Supplemental Table 3. Factors Associated with Risk of Survival Including Receipt of Subsequent MF Treatment